Details for New Drug Application (NDA): 218281
✉ Email this page to a colleague
NDA 218281 describes ERIBULIN MESYLATE, which is a drug marketed by Baxter Hlthcare Corp, Gland Pharma Ltd, Jiangxi Qingfeng, and Long Grove Pharms, and is included in four NDAs. It is available from five suppliers. Additional details are available on the ERIBULIN MESYLATE profile page.
The generic ingredient in ERIBULIN MESYLATE is eribulin mesylate. Seven suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.
The generic ingredient in ERIBULIN MESYLATE is eribulin mesylate. Seven suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.
Summary for 218281
| Tradename: | ERIBULIN MESYLATE |
| Applicant: | Jiangxi Qingfeng |
| Ingredient: | eribulin mesylate |
| Patents: | 0 |
Pharmacology for NDA: 218281
| Physiological Effect | Microtubule Inhibition |
Suppliers and Packaging for NDA: 218281
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 218281 | ANDA | HIKMA PHARMACEUTICALS USA INC. | 0143-9167 | 0143-9167-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0143-9167-01) / 2 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1MG/2ML (0.5MG/ML) | ||||
| Approval Date: | Jun 28, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
